Rapport Presents Phase 2 Data for Epilepsy Drug RAP-219
BOSTON & SAN DIEGO, USA — April 1, 2026 Rapport Therapeutics, Inc. announced that it will present new Phase...
Neurology
Advertisement
Ionis Zilganersen NDA Gets FDA Priority Review
CARLSBAD, California, March 23, 2026 Ionis Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted...
Vasomune AV-001 Trial Begins for Brain Protection
TORONTO, CANADA | March 24, 2026 A significant milestone has been reached in clinical-stage biopharmaceutical research as the first...
LT3001 Stroke Drug Shows Phase 2 Functional Gains
Taipei, Taiwan — February 6, 2026 Lumosa Therapeutics has announced positive Phase 2 clinical trial outcomes for LT3001 (odatroltide),...
FDA Clears Neurophet AQUA AD Plus in Alzheimer’s AI
Seoul, South Korea — February 6, 2026 Neurophet has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
AEON Biopharma Posts Q3 Gains with Strong ABP-450 Biosimilarity Data
IRVINE, CA — November 14, 2025 — AEON Biopharma announced its third-quarter 2025 financial results, highlighting strong operational progress,...
Gate Bioscience Raises $65M to Advance Molecular Gates
BRISBANE, CA – November 13, 2025 — Gate Bioscience announced the closing of an oversubscribed $65 million Series B...
Northwestern Scientists Develop Model to Predict Risk of Sudden Death in Epilepsy Patients
CHICAGO, IL – November 11, 2025 — Scientists at Northwestern University Feinberg School of Medicine have developed a novel...
Praxis Secures $525M to Boost CNS Drug Development
BOSTON, October 16, 2025 Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, has announced the successful pricing...
AB Science Secures €2.8 Million in Private Placement to Advance Clinical Pipeline
PARIS, October 17, 2025 AB Science S.A., a biopharmaceutical company focused on discovering, developing, and marketing protein kinase inhibitors,...
Advertisement
